The Priority Review

Clinical trials Brief

Pfizer registers Phase 3 trial of berobenatide in women with stress urinary incontinence and obesity

The study, titled VESPER-SUI, plans to enroll 900 participants and has a planned start date of November 17, 2026. It aims to learn about the safety and effectiveness of berobenatide in adult women with stress urinary incontinence and obesity or overweight.

Primary source

ClinicalTrials.gov registry record, November 12, 2026

The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight

Read the source: The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or Overweight clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation